Migraine clinical trials

Explore recruiting migraine clinical trials.

Recruiting migraine studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Migraine trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2

France, Germany, Spain, Italy, Belgium, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine

Spain, Denmark, Germany, Hungary, France, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4951009: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age

France, Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4951013 - AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE

Hungary, Italy, Spain, Czechia, Poland, Finland +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Longterm, openlabel (doseblinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine

Italy, Portugal, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications

Belgium, Germany, Sweden, Austria, Denmark, Finland +3 more

Therapeutic use (Phase IV) EU CTIS Study details

Migraine trials by city

Migraine in Toronto Migraine in Vancouver Migraine in Montreal Migraine in Calgary Migraine in Edmonton Migraine in Ottawa Migraine in Winnipeg Migraine in Quebec City Migraine in Hamilton Migraine in Kitchener Migraine in London Migraine in Halifax Migraine in New York Migraine in Los Angeles Migraine in Chicago Migraine in Houston

Other conditions

Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease IgA nephropathy Polycystic kidney disease Alzheimer's disease Parkinson's disease Multiple sclerosis Epilepsy ALS Huntington's disease Peripheral neuropathy Restless legs syndrome Essential tremor Dementia Depression Anxiety